Endocrine Pharmacology Practice Questions

Q: Bisphosphonates are prescribed to a patient with which of the following advice?

Take on an empty stomach with plenty of water. **Explanation:** **1. Why Option A is Correct:** Bisphosphonates (e.g., Alendronate, Risedronate) have extremely **poor oral bioavailability** (typically <1%). Their absorption is significantly further impaired by the presence of food, calcium, or iron supplements. Therefore, they must be taken on an **empty stomach** (at least 30 minutes before breakfast) with a full glass of **plain water** to ensure adequate systemic absorption. **2. Why Other Options are Incorrect:** * **Option B:** Taking them after meals would render the drug virtually ineffective due to negligible absorption. * **Option C:** While bisphosphonates can cause esophageal irritation, "gastritis" is not a definitive reason to discontinue the drug immediately [1]. Instead, patients are advised to **remain upright for 30–60 minutes** after ingestion to prevent gastroesophageal reflux and esophagitis. * **Option D:** While "atypical femoral fractures" are a rare long-term complication, transient musculoskeletal pain is a known side effect that usually does not require permanent discontinuation unless severe or indicative of a fracture [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** They inhibit **osteoclast activity** by interfering with the mevalonate pathway (specifically inhibiting farnesyl pyrophosphate synthase) [2]. * **The "Upright Rule":** To prevent the most common side effect—**erosive esophagitis**—patients must not lie down after taking the pill. * **Major Side Effects:** 1. **Osteonecrosis of the Jaw (ONJ):** Especially with IV forms (Zoledronate). 2. **Atypical Subtrochanteric Fractures:** Associated with long-term use (>5 years). * **Drug of Choice:** Bisphosphonates are the first-line treatment for **Postmenopausal Osteoporosis** and **Paget’s disease** [1].

Q: Which of the following is NOT true for octreotide?

Used orally. **Explanation:** **Octreotide** is a synthetic long-acting analogue of **Somatostatin** (Growth Hormone Inhibiting Hormone) [1]. 1. **Why Option B is Correct (The False Statement):** Octreotide is a peptide molecule [1]. Like insulin and other peptides, it is susceptible to degradation by gastrointestinal enzymes and has poor mucosal permeability. Therefore, it **cannot be administered orally**. It must be given via **parenteral routes** (Subcutaneous or Intravenous) [3], [5]. 2. **Analysis of Other Options:** * **Option A (Acromegaly):** Octreotide is a first-line medical therapy for acromegaly [3]. It binds to somatostatin receptors (SSTR-2 and SSTR-5) to potently inhibit the secretion of Growth Hormone (GH) and IGF-1 [2], [5]. * **Option C (Secretory Diarrhea):** It is highly effective in controlling secretory diarrhea associated with **Carcinoid syndrome** and **VIPomas** by inhibiting intestinal fluid secretion and slowing GI motility [4]. * **Option D (Portal Hypertension):** In acute variceal bleeding, octreotide is used to reduce portal venous pressure [5]. It causes **splanchnic vasoconstriction** (by inhibiting the release of glucagon and other vasodilatory peptides), thereby reducing blood flow to the portal system [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Octreotide has a much longer half-life (~1.5–2 hours) compared to natural somatostatin (~2–3 minutes) [1], [4]. * **Side Effects:** The most characteristic side effect is the formation of **steatorrhea** and **gallstones (cholelithiasis)** due to the inhibition of cholecystokinin (CCK) release and gallbladder contractility [3], [5]. * **Other Uses:** It is also used in the management of **Zollinger-Ellison Syndrome**, **Insulinomas**, and to reduce output from **pancreatic fistulas**.

Q: Which of the following corticosteroids has the least mineralocorticoid activity?

Triamcinolone. **Explanation:** The potency of corticosteroids is determined by their relative **glucocorticoid** (anti-inflammatory) and **mineralocorticoid** (salt-retaining) activities. **Why Triamcinolone is the correct answer:** Glucocorticoids are classified based on their duration of action and side-effect profile. **Triamcinolone**, along with **Dexamethasone** and **Betamethasone**, is a synthetic steroid designed to maximize anti-inflammatory effects while minimizing mineralocorticoid activity. However, among the options provided, Triamcinolone is traditionally classified as having **zero (negligible)** mineralocorticoid activity. While Dexamethasone and Betamethasone also have minimal salt-retaining effects, Triamcinolone is the classic textbook answer for the "least" or "nil" mineralocorticoid activity in this comparative group. **Analysis of Incorrect Options:** * **Fludrocortisone (A):** This is a potent mineralocorticoid. It has the highest salt-retaining activity among the options and is used clinically for replacement therapy in Addison’s disease. * **Dexamethasone (B) & Betamethasone (D):** These are long-acting, highly potent glucocorticoids. While they have negligible mineralocorticoid activity, they are often ranked slightly behind Triamcinolone in terms of pure "zero" salt retention in comparative pharmacology tables. **High-Yield NEET-PG Pearls:** * **Highest Mineralocorticoid Potency:** Fludrocortisone > Aldosterone > Desoxycorticosterone acetate (DOCA). * **Highest Glucocorticoid Potency:** Betamethasone > Dexamethasone > Triamcinolone > Prednisolone > Hydrocortisone. * **Drug of Choice for Cerebral Edema:** Dexamethasone (due to high potency and low salt retention). * **Fetal Lung Maturity:** Betamethasone or Dexamethasone are used because they cross the placenta and have low protein binding. * **Triamcinolone side effect:** It is specifically associated with muscle wasting (myopathy) more than other steroids.

Q: Mestranol acts as a contraceptive by:

Inhibiting FSH secretion. **Explanation:** **Mestranol** is a synthetic estrogen and a prodrug of ethinyl estradiol, commonly used in combined oral contraceptive pills (COCPs). **1. Why Option A is Correct:** The primary mechanism of the **estrogen component** (like Mestranol) in COCPs is the **suppression of Follicle Stimulating Hormone (FSH)** via negative feedback on the anterior pituitary. By inhibiting FSH, the recruitment and maturation of ovarian follicles are prevented, ensuring there is no dominant follicle to release an egg. **2. Why Other Options are Incorrect:** * **Option B (Inhibiting LH secretion):** This is the primary mechanism of the **Progestogen component**. Progesterone suppresses Luteinizing Hormone (LH) surge, thereby preventing ovulation. While estrogen contributes to this, its hallmark action is FSH suppression. * **Option C (Inhibiting tubal motility):** This is a secondary effect of **Progesterone**, which alters the contractility of the fallopian tubes to slow down ovum/zygote transport. * **Option D (Inhibiting nidation):** This refers to making the endometrium unfavorable for implantation, another secondary effect primarily mediated by **Progesterone** (causing early secretory changes and subsequent atrophy). **Clinical Pearls for NEET-PG:** * **Mestranol vs. Ethinyl Estradiol:** Mestranol is less potent because it must be converted to ethinyl estradiol in the liver. * **The "Double Lock" Mechanism:** COCPs are highly effective because they inhibit ovulation through two pathways: Estrogen (FSH suppression) + Progesterone (LH surge suppression). * **Hostile Cervical Mucus:** The most important contraceptive effect of progestogen-only pills (Mini-pills) is thickening the cervical mucus to prevent sperm penetration.

Q: Saheli or Centchroman contains which of the following active pharmaceutical ingredients?

Ormeloxifene. **Explanation:** **Correct Option: C. Ormeloxifene** Saheli (Centchroman) is a unique, non-steroidal oral contraceptive pill developed by the Central Drug Research Institute (CDRI), Lucknow. Its active ingredient is **Ormeloxifene**, which belongs to the class of **Selective Estrogen Receptor Modulators (SERMs)**. The mechanism of action is based on its competitive antagonism of estrogen receptors in the uterus. By blocking these receptors, it prevents the normal proliferative changes in the endometrium, making it asynchronous and unsuitable for implantation. It also alters cervical mucus and increases tubal motility. Because it is non-steroidal, it does not suppress ovulation, meaning the hypothalamic-pituitary-ovarian axis remains intact. **Incorrect Options:** * **A & D (Estrogen + Progesterone / Steroids):** Traditional Combined Oral Contraceptive Pills (COCPs) contain steroids (Ethinylestradiol and Progestogens). Saheli is specifically marketed as a **non-steroidal** alternative, avoiding side effects like weight gain, nausea, and increased risk of thromboembolism. * **B (Raloxifene):** While Raloxifene is also a SERM, it is primarily used for the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer, not as a contraceptive. **High-Yield Clinical Pearls for NEET-PG:** * **Dosage Schedule:** It is taken **twice weekly** for the first 3 months (e.g., Sunday and Wednesday), followed by **once weekly** thereafter. * **Failure Rate:** The Pearl Index is approximately **1.83 to 1.96**. * **Side Effects:** The most common side effect is **delayed menstrual cycles** (prolonged cycles), which occurs in about 8% of users. * **Contraindications:** Polycystic Ovarian Syndrome (PCOS), cervical dysplasia, and recent history of jaundice or liver disease. * **Government Program:** It is included in the National Family Planning Program of India under the brand name **'Chhaya'**.

Q: Which of the following is a serious adverse effect seen with zoledronate?

Acute renal failure. **Explanation:** **Zoledronate (Zoledronic acid)** is a high-potency, intravenous nitrogen-containing bisphosphonate used primarily for osteoporosis, Paget’s disease, and bone metastases. **Why Acute Renal Failure is the correct answer:** Zoledronate is excreted unchanged by the kidneys. When administered intravenously, especially if infused too rapidly (less than 15 minutes) or in dehydrated patients, it can cause **acute tubular necrosis (ATN)**. It leads to a transient increase in serum creatinine and, in severe cases, acute renal failure. Therefore, monitoring creatinine clearance and ensuring adequate hydration before administration is mandatory. **Analysis of Incorrect Options:** * **B. Ventricular fibrillation:** While bisphosphonates (especially zoledronate) have been associated with an increased risk of **Atrial Fibrillation** in some trials, they are not typically associated with ventricular fibrillation. * **C. Peptic ulcer:** This is a classic side effect of **oral bisphosphonates** (like Alendronate) due to direct esophageal and gastric mucosal irritation. Since Zoledronate is given IV, it bypasses the GI tract and does not cause peptic ulcers. * **D. Anterior uveitis:** While bisphosphonates can cause ocular inflammation (like scleritis or uveitis), it is considered a rare idiosyncratic reaction rather than a common "serious" adverse effect compared to the systemic impact of renal failure. **High-Yield Clinical Pearls for NEET-PG:** * **Osteonecrosis of the Jaw (ONJ):** A high-yield adverse effect associated with long-term, high-dose IV bisphosphonate therapy, often triggered by invasive dental procedures. * **Acute Phase Reaction:** Patients often experience flu-like symptoms (fever, myalgia) within 24–72 hours of the first IV infusion. * **Contraindication:** Zoledronate is generally contraindicated if Creatinine Clearance (CrCl) is **<35 mL/min**.

Q: Which of the following drugs has visual field defects as an adverse effect?

Pegvisomant. **Explanation:** **Correct Option: C. Pegvisomant** Pegvisomant is a **Growth Hormone (GH) receptor antagonist** used in the treatment of acromegaly. It works by blocking the peripheral action of GH, thereby reducing the production of Insulin-like Growth Factor-1 (IGF-1). The mechanism behind **visual field defects** with Pegvisomant is unique: because it effectively lowers IGF-1 levels, it removes the negative feedback inhibition on the pituitary gland. This can lead to a compensatory **increase in GH secretion** and, more importantly, potential **growth of the underlying pituitary adenoma**. As the tumor expands (adenoma progression), it can compress the **optic chiasm**, resulting in bitemporal hemianopia or other visual field defects. Regular MRI monitoring of the pituitary is mandatory during therapy. **Incorrect Options:** * **A & B (Cabergoline & Bromocriptine):** These are Dopamine (D2) agonists used to treat prolactinomas and acromegaly. They typically cause **tumor shrinkage**, which helps *improve* visual field defects rather than causing them. * **D (Leuprolide):** This is a GnRH analog used for prostate cancer and precocious puberty. Its side effects are primarily related to hypoestrogenism/hypoandrogenism (e.g., hot flashes, bone loss), not visual field changes. **High-Yield Clinical Pearls for NEET-PG:** * **Pegvisomant:** Most potent drug for normalizing IGF-1 levels in acromegaly. * **Monitoring:** Liver Function Tests (LFTs) must be monitored as it can cause asymptomatic elevation of liver enzymes. * **Acromegaly Treatment Hierarchy:** Surgery is the first line; Somatostatin analogs (Octreotide) are the first-line medical therapy; Pegvisomant is used for resistant cases.

Q: A young female presents with a history of intercourse 5 hours prior. Select the drug that can act as a single-dose postcoital contraceptive.

Mifepristone. **Explanation:** **Mifepristone (Option B)** is a potent competitive antagonist at progesterone receptors. In the context of emergency contraception, it acts by delaying or inhibiting ovulation (if taken pre-ovulatory) and altering the endometrium to prevent implantation (if taken post-ovulatory). A single dose of **10–25 mg** is highly effective as a postcoital contraceptive and is often preferred due to fewer side effects (like nausea/vomiting) compared to the Yuzpe regimen. **Analysis of Incorrect Options:** * **Clomiphene citrate (A):** A Selective Estrogen Receptor Modulator (SERM) used primarily for **ovulation induction** in infertility; it would be counterproductive in this scenario. * **Danazol (C):** An androgen derivative used in endometriosis and hereditary angioedema. While it was historically used for emergency contraception, it requires multiple doses and is far less effective and more toxic than modern options. * **Medroxyprogesterone acetate (D):** A progestin used for long-term contraception (DMPA injections) or menstrual cycle regulation. It is not used as a single-dose emergency contraceptive. **High-Yield NEET-PG Pearls:** * **Levonorgestrel (LNG):** The most common single-dose emergency contraceptive (1.5 mg) used within 72 hours. * **Ulipristal Acetate:** A Selective Progesterone Receptor Modulator (SPRM) effective up to **120 hours (5 days)** post-intercourse. * **Copper T (IUCD):** The **most effective** emergency contraceptive method if inserted within 5 days. * **Mifepristone Dosing:** 10–25 mg for emergency contraception; 200 mg (combined with Misoprostol) for medical abortion.

Question 1

Bisphosphonates are prescribed to a patient with which of the following advice?

Accepted Answer

Take on an empty stomach with plenty of water

Answer

Take after meals

Answer

Discontinue if gastritis develops

Answer

Discontinue if severe bone pain occurs

Question 2

Which of the following is NOT true for octreotide?

Accepted Answer

Used orally

Answer

Used in Acromegaly

Answer

Given in secretory diarrhea

Answer

Used in portal hypertension

Question 3

A 52-year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is MOST likely to lead them to select raloxifene?

Accepted Answer

Strong family history of breast cancer

Answer

Previous hysterectomy

Answer

Recurrent vaginitis

Answer

Troublesome hot flushes

Question 4

Which of the following corticosteroids has the least mineralocorticoid activity?

Accepted Answer

Triamcinolone

Answer

Fludrocortisone

Answer

Dexamethasone

Answer

Betamethasone

Question 5

Mestranol acts as a contraceptive by:

Accepted Answer

Inhibiting FSH secretion

Answer

Inhibiting LH secretion

Answer

Inhibiting tubal motility

Answer

Inhibiting nidation

Question 6

Which corticosteroid has the maximum sodium-retaining potential?

Accepted Answer

Fludrocortisone

Answer

Hydrocortisone

Answer

Prednisolone

Answer

Deoxycorticosterone

Question 7

Saheli or Centchroman contains which of the following active pharmaceutical ingredients?

Accepted Answer

Ormeloxifene

Answer

Estrogen + progesterone

Answer

Raloxifene

Answer

Steroid

Question 8

Which of the following is a serious adverse effect seen with zoledronate?

Accepted Answer

Acute renal failure

Answer

Ventricular fibrillation

Answer

Peptic ulcer

Answer

Anterior uveitis

Question 9

Which of the following drugs has visual field defects as an adverse effect?

Accepted Answer

Pegvisomant

Answer

Cabergoline

Answer

Bromocriptine

Answer

Leuprolide

Question 10

A young female presents with a history of intercourse 5 hours prior. Select the drug that can act as a single-dose postcoital contraceptive.

Accepted Answer

Mifepristone

Answer

Clomiphene citrate

Answer

Danazol

Answer

Medroxyprogesterone acetate

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?